The expansion will include Ripple’s Epidel platform, which delivers sustained-release pharmaceuticals with surface erosion release kinetics without the use of polymers or excipients, according to a March 20 news release from Hovione.
Epidel enables higher drug loading, smaller size implants, and defined and predictable biocompatible degradation products, the release said.
By incorporating Epidel, Hovione can expand its portfolio throughout the pharmaceutical industry, according to the release.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.